News | November 23, 2023
Merck to acquire Caraway Therapeutics
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
Evinova will operate as a separate health-tech business within AstraZeneca
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Phase 3 data expected in the second half of 2024
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Subscribe To Our Newsletter & Stay Updated
